BioCryst Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $163,353 | $145,534 | $131,534 | $117,085 |
Gross Profit | 160,555 | 140,966 | 125,403 | 113,857 |
EBITDA | 28,397 | 24,583 | -1,233 | 11,692 |
EBIT | 28,068 | 24,252 | -1,542 | 11,381 |
Net Income | 5,085 | 32 | -26,795 | -14,033 |
Net Change In Cash | 163,353 | 145,534 | 131,534 | 117,085 |
Free Cash Flow | 41,123 | -27,660 | -5,888 | 8,186 |
Cash | 88,525 | 105,190 | 104,713 | 96,841 |
Basic Shares | 219,886 | 215,261 | 207,381 | 206,905 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $450,712 | $331,412 | $270,827 | $157,170 |
Gross Profit | 438,443 | 325,096 | 262,796 | 149,129 |
EBITDA | 12,808 | -116,335 | -143,854 | -121,738 |
EBIT | 11,562 | -117,990 | -145,291 | -122,515 |
Net Income | -88,881 | -226,539 | -247,116 | -184,062 |
Net Change In Cash | 450,712 | 331,412 | 270,827 | 157,170 |
Cost of Revenue | 233,386 | |||
Free Cash Flow | -53,144 | -97,309 | -163,201 | -144,542 |
Cash | 104,713 | 110,643 | 304,767 | 504,389 |
Basic Shares | 206,696 | 192,198 | 185,908 | 179,117 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.15 |
2025-03-31 | $0.0001 |
2024-12-31 | -$0.13 |
